Results of a new retrospective study have been presented at the North American Neuromodulation Society 17th annual meeting in Las Vegas this week. New retrospective data highlighting the Boston Scientific Corporation points to the data on its Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate the device provided highly significant pain relief three months after implantation.
Spinal cord stimulators work by delivering electrical pulses from an implantable pulse generator to leads with stimulating contacts that mask pain signals travelling to the brain.
Boston Scientific says its Precision Spectra is the first SCS System designed to improve pain relief using the innovative and highly advanced Illumina 3D Software, a three dimensional anatomy-driven computer model. By providing twice the number of contacts available with other SCS systems the company believes its Precision Spectra System offers more coverage of the spinal cord for the management of chronic pain.
The newly presented retrospective study of up to 213 consecutive patients at 13 centers focused on patients with chronic pain who were treated with the Precision Spectra SCS System. Results included a 94% SCS trial therapy success rate (n=213), and a highly significant reduction in pain from an average baseline score of 7.8, on a 10-point scale, to an average score of 3.2 at three months post implant (in the patients who have reached the three-month follow up, n=113).
Low back pain patients who reached the three-month follow up (n=32) yielded a highly significant reduction in low back pain from an average baseline score of 7.0, on a 10-point scale, to an average of 2.9.
Overall early results indicated improvements in function, including walking and sleeping, in addition to reductions in opioid use and disability.
“The primary objective of SCS is pain relief,” said Salim Hayek, M.D., Ph.D., chief, Division of Pain Medicine at University Hospitals of Cleveland. “These initial results indicate that the Precision Spectra System is effectively reducing pain in these real-world patients at three months post implant.”
“Boston Scientific is committed to advancing science to improve pain relief,” said Maulik Nanavaty, president, Neuromodulation, Boston Scientific. “These data are very promising and we look forward to the results of our ongoing clinical programs to demonstrate the long term benefits of the Precision Spectra SCS System.”
Source: Boston Scientific Corporation., PR Newswire